Drug-Eluting Balloon Catheters Market - By Product (Coronary Artery Disease Drug-Eluting Balloon Catheters {Paclitaxel, Sirolimus}, Peripheral Vascular Disease Drug-Eluting Balloon Catheters {Paclitaxel, Sirolimus}), By End-use & Forecast, 2022 -2030

Industry Overview

Drug-eluting Balloon Catheters Market size was valued at over USD 450 million in 2021. Driven by a growing number of patients suffering from peripheral and cardiovascular diseases, the market is poised to grow at over 10.5% CAGR from 2022 to 2030.
 

To get more details on this report: Request Free Sample PDF
 

Increasing geriatric population has contributed to the higher occurrence of aging-associated diseases such as cardiovascular and coronary artery disease, elevating the demand for catheters and is positively impacting the market outlook.
 

High risk of infections associated with drug-eluting balloon catheters may hinder industry development

Despite a rising scope for product adoption, factors such as the high infection risks associated with catheterization procedures and balloon catheters may adversely impact the industry landscape. While rare, instances of septic complications due to post-percutaneous transluminal coronary artery angioplasty and cardiac catheterization are likely to grow with the widening patient pool. This may create an obstruction for the industry in the coming years.
 

However, the implementation of stringent sterilization standards, which reduce the chances of local or systemic infection, for patients that have undergone cardiac catheterization procedures is likely to mitigate the impact to a certain degree.
 

Rising incidence of cardiac diseases to drive segment expansion

To get more details on this report: Request Free Sample PDF
 

On the basis of product, the drug-eluting balloon catheters market is categorized into peripheral vascular disease drug-coated balloon catheters and coronary artery disease DCB catheters. Amongst them, coronary artery disease DCB catheters segment is poised to amass over USD 510 million by 2030, fueled by the increasing prevalence of cardiac disorders in the world. The growth can also be credited to the product’s application in the treatment of restenosis. Coronary artery disease DCB catheters are also commonly used for revascularization, to help reinstate blood flow to blocked veins and arteries, which is further fostering segment outlook.
 

Shifting patient preference to drive industry size through ambulatory surgical centers

To get more details on this report: Request Free Sample PDF
 

Drug-eluting balloon catheters market from ambulatory surgical centers segment (ASCs) is slated to register over USD 400 million by 2030. This is credited to shifting patient preference towards ambulatory surgical centers (ASCs) owing to their affordability and quality treatment facilities. Incorporation of advanced equipment and technology at ASCs is also responsible for augmenting segment scenario. In addition, several other vital attributes, including the ability of ASCs to provide low-risk surgeries and more convenient treatment settings are also fostering the segment’s revenue.
 

Increasing chronic disorders to outline the North America market progress

North America drug-eluting balloon catheters market is poised to surpass USD 440 million by 2030, owing to rising occurrence of chronic disorders in the region. As per the National Institute of Diabetes and Digestive and Kidney Disease 2021 report, nearly 37 million people in America have chronic kidney disease, which accounts for 1 in 7 adults requiring catheterization for treatment. This is due to rising awareness, favorable government initiatives, and the region’s well-developed healthcare infrastructure.
 

Mergers and acquisitions to define the competitive landscape

The list of drug-eluting balloon catheters market players includes names such as B. Braun Melsungen AG, Medtronic, BD Interventional, Biotronik AG, Eurocor GmbH, MedAlliance, Boston Scientific Corporation, and others. Many companies have recently turned to mergers and acquisitions to extend their global footprint. In February 2022, for instance, Boston Scientific Corporation, a leading biotechnology engineering firm and medical device manufacturer, acquired Baylis Medical Company Inc., a high-technology medical device supplier to expand its geographical footprint, target new markets, and generate revenue.
 

Impact of COVID-19 on the drug-coated balloon catheters market trends

The COVID-19 pandemic had a severe impact on drug-eluting balloon catheters industry, due to the delayed peripheral, interventional, and cardiovascular surgical procedures. Many nations prioritized the treatment of the coronavirus patients due to prevent the high case counts from overwhelming the system. Hospitals also delayed all non-emergency procedures, including catheterization, to divert resources towards pandemic patient treatment and care.
 

This drug-coated balloon catheters market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Billion from 2017 to 2030 for the following segments:

Click here to Buy Section of this Report

By Product

• Coronary artery disease drug-eluting balloon catheters
  • Paclitaxel
  • Sirolimus
• Peripheral vascular disease drug-eluting balloon catheters
  • Paclitaxel
  • Sirolimus

By End-use

• Hospitals and clinics
• Ambulatory Surgical Centers
• Catheterization Laboratories

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE